Tariff-related Litigation Update

Explore the impact of the Supreme Court’s decision in Kennedy v. Braidwood on the ACA preventive services mandate and its implications for MedTech policy.

Member-only overview of IEEPA reciprocal & “fentanyl” tariffs under EO 14257, summarizing key federal court challenges and rulings through June 17, 2025.

Member-only summary of IEEPA “fentanyl” and reciprocal tariffs under EO 14257, plus status of related legal challenges across federal courts through June 17, 2025.

AdvaMed President and CEO Scott Whitaker testified before the U.S. Senate Finance Committee, bringing attention to the pressing issue of how tariffs could impact the medtech industry and, most importantly, the patients who depend on it. 

Emergency Briefing on Court Ruling on Tariffs and Its Impact on Medtech. Now On Demand!

Bern/Washington – Swiss Medtech, the leading trade association for medical technology companies in Switzerland, and AdvaMed, the U.S. Medtech Association and the world’s largest organization representing medtech innovators, are jointly calling for reciprocal “zero for zero” tariffs between the two countries.

The U.S. Supreme Court is reviewing Braidwood Management v. Becerra, a high-stakes case challenging the authority of the U.S. Preventive Services Task Force (USPSTF) under the Affordable Care Act. At the heart of the case is whether USPSTF recommendations—used to mandate insurance coverage for preventive services—are constitutionally valid.

WASHINGTON – Today, President and CEO Scott Whitaker of AdvaMed, the Medtech Association, testified before the U.S. Senate Committee on Finance in its hearing focused on the impact of tariffs on U.S. supply chains. AdvaMed was the only health care organization invited to discuss the medical technology supply chain.